NCT06491446 2026-02-18
Evaluating Clearance of High-Risk HPV and Safety After Administration of ABI-2280 Vaginal Inserts
Antiva Biosciences
Phase 1/2 Active not recruiting
Clinical Trials
14 trialsNCT06632912 2026-01-23
Phase IIIb Clinical Trial of Quadrivalent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) for Age/Immunization Schedule Bridging
National Vaccine and Serum Institute, China
Phase 3 Active not recruiting
NCT04724980 2025-06-11
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
Precigen, Inc
Phase 1/2 Active not recruiting
NCT05555862 2025-05-18
anal HSIL HIV-
Frantz Viral Therapeutics, LLC
Phase 2 Active not recruiting
NCT06959563 2025-05-13
9vHPV-BCG
Medicine Invention Design, Inc
Phase EARLY_PHASE1 Active not recruiting
NCT04708041 2025-04-20
V503-069
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04199689 2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06454175 2025-01-06
A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years
Shanghai Bovax Biotechnology Co., Ltd.
Phase 1 Active not recruiting
NCT05285826 2024-12-16
Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02653118 2024-11-12
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Merck Sharp & Dohme LLC
Active not recruiting
NCT06041061 2023-09-18
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
Sinocelltech Ltd.
Phase 3 Active not recruiting
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT03998254 2022-11-16
V503-023
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05450705 2022-09-02
V503-071
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting